Alzheimer's Disease

Recently Updated
FDA Notice Calls CBD "Beneficial" Last Updated on 2017-08-23 19:35:25 Cannabis Business Times | August 21st 2017 | Melissa Schiller In an Aug. 14 notice requesting public comments for a UN drug committee, the U.S. Food and Drug Administration (FDA) said CBD was the only beneficial substance on the international committee’s list of 17 substances under review. In the descriptions of the substances under review, the FDA stated, “CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy. In the United States, CBD-containing products are in human clinical testing in three therapeutic areas, but no such products are approved by FDA for marketing for medical purposes in the United States.” The notice goes on to say that CBD is a Schedule I controlled substance under the Controlled Substances Act (CSA). The FDA is looking for public input on CBD’s (and the... More »
CBD Beneficial Effects on Parkinson's, Alzheimer's & MS Last Updated on 2017-07-24 13:28:36 Mannucci C1, Navarra M1, Calapai F1, Spagnolo EV2, Busardò FP3, Da Cas R4, Ippolito FM4, Calapai G1.   Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound with a broad spectrum of potential therapeutic properties, including neuroprotective effects in numerous pathological conditions. CBD neuroprotection is due to its antioxidant and antiinflammatory activi-ties and the modulation of a large number of brain biological targets (receptors, channels) involved in the development and maintenance of neurodegenerative diseases. Aim of the present review was to describe the state of art about the pre-clinical research, the potential use and, when existing, the clinical evidence related to CBD in the neurological field. Collection of all the... More »
Cannabinol (CBD) delays symptom onset Last Updated on 2017-07-18 17:27:19 Weydt P1, Hong S, Witting A, Möller T, Stella N, Kliot M.   Therapeutic options for amyotrophic lateral sclerosis (ALS), the most common adult-onset motor neuron disorder, remain limited. Emerging evidence from clinical studies and transgenic mouse models of ALS suggests that cannabinoids, the bioactive ingredients of marijuana (Cannabis sativa) might have some therapeutic benefit in this disease. However, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the predominant cannabinoid in marijuana, induces mind-altering effects and is partially addictive, compromising its clinical usefulness. We therefore tested whether cannabinol (CBN), a non-psychotropic cannabinoid, influences disease progression and survival in the SOD1 (G93A) mouse model of ALS. CBN was delivered via subcutaneously implanted osmotic mini-pumps (5 mg/kg/day) over a period of up to 12 weeks. We found... More »
Marijuana's Active Ingredient Shown to Inhibit Primary Marker of Alzheimer's Disease Last Updated on 2017-07-18 17:23:00 Marijuana's Active Ingredient Shown to Inhibit Primary Marker of Alzheimer's Disease Discovery Could Lead to More Effective Treatments LA JOLLA, CA, August 9, 2006 - Scientists at The Scripps Research Institute have found that the active ingredient in marijuana, tetrahydrocannabinol or THC, inhibits the formation of amyloid plaque, the primary pathological marker for Alzheimer's disease. In fact, the study said, THC is "a considerably superior inhibitor of [amyloid plaque] aggregation" to several currently approved drugs for treating the disease. The study was published online August 9 in the journal Molecular Pharmaceutics, a publication of the American Chemical Society. According to the new Scripps Research study, which used both computer modeling and biochemical assays, THC inhibits the enzyme acetylcholinesterase (AChE), which acts as a... More »
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease Last Updated on 2017-07-18 17:16:56 Frontiers in Pharmacology Georgia Watt1 and Tim Karl1,2,* Author information ► Article notes ► Copyright and License information ► This article has been cited by other articles in PMC.   Go to: Abstract Alzheimer's disease (AD) is a debilitating neurodegenerative disease that is affecting an increasing number of people. It is characterized by the accumulation of amyloid-β and tau hyperphosphorylation as well as neuroinflammation and oxidative stress. Current AD treatments do not stop or reverse the disease progression, highlighting the need for new, more effective therapeutics. Cannabidiol (CBD) is a non-psychoactive phytocannabinoid that has demonstrated neuroprotective, anti-inflammatory and antioxidant properties in vitro. Thus, it is investigated as a potential multifunctional treatment option for AD. Here, we summarize the current status quo... More »